GLP-1 cash price index: $333 a month in September 2026

The three numbers

Written and edited by John SamarasAbout this siteContact

The gap between the two routes was $100 a month in September 2026. Branded cost 1.5x the compounded route. Compounded medications are not FDA-approved products, and they are not the same product as the branded drug.

What moved in September 2026

No tracked price moved in September 2026. Every program was checked against its own published page each Monday. One program changed product. It is named under who joined and who left.

Who joined and who left

The change from August counts only programs priced in both months. The rest are named here.

• Joined. Henry Meds at $297/mo, first priced September 14, 2026.
• Left. Mochi Health was delisted on September 14, 2026. It was $178/mo in August.
• Changed product. Sam's Club Member Health: Wegovy pill replaced by Zepbound pen on September 7, 2026, $299 to $399/mo.
• Corrected. Costco / Success by Sesame, Found, Lemonaid Health, Ro Body, Sesame Care and Shed carry the rate GLP Chart publishes today back into August.
• As published. The September 2026 release put the August median at $348 under method 1.0, and that page stands unchanged.

What a pharmacy pays for the same month

The CMS National Average Drug Acquisition Cost survey records what US retail pharmacies pay their wholesaler. It is an acquisition-cost benchmark. It is not pharmacy margin: the distance to a cash price also covers dispensing, the clinician visit, shipping and the seller's own costs, and a manufacturer selling direct does not buy through a wholesaler at all. NADAC dashboards have been published free by 46brooklyn Research since 2019. What is added here is the join to verified consumer cash prices.

A month of branded Wegovy cost a US pharmacy $1,302 to acquire in September 2026, against $299 for the cheapest verified cash route in this index, according to GLP Chart's reading of the CMS NADAC file effective August 19, 2026.

Packaging, same drug, same dose

Lilly sells Zepbound as single-dose pens and as a multi-dose KwikPen. At the same dose a pharmacy pays different money for each.

The series

One row per month since the weekly record opened. The monthly value is the median of that month's weekly checks. Earlier months are recomputed on today's corrected record, so a row can differ from the figure an earlier release published.

Method, version 2.0

• Universe. Every program in the GLP Chart index that is active, prices in cash rather than an insurance copay, and publishes an all-in monthly price.
• Compounded semaglutide route. Programs publishing one flat all-in monthly price covering compounded semaglutide at every dose. Entry and starting-dose prices are excluded.
• Branded route. Programs whose primary supply is branded medication and whose maintenance pricing is verified rather than estimated.
• The monthly value. Each week we take the median, or the lowest, price across every program priced that week, and the month's value is the median of those weekly figures.
• Month on month. The change from the prior month counts only programs priced in both months, with any price we later corrected carried back into the prior month, so a program joining, leaving or being corrected never reads as a price move.
• Product changes. A program that changes which drug or product its price covers counts as leaving and joining again, and the switch is named with its date and both prices.
• What changed in version 2.0. Version 2.0 replaces version 1.0's fixed panel. Version 1.0 took the median over the programs priced in every weekly check since May 2026 and set it against the prior month's figure, so a program leaving, a program returning or a price we corrected could move the headline.
• Prepaid rates. An observation equal to a program's published 12-month prepaid monthly rate is dropped, and a program whose only published rate is a block of months bought up front is left out.
• Excluded. Insurance copays, introductory and starter-dose rates, prepaid plan rates, and programs that publish no ongoing price.
• Classification. Programs are classified by the pricing model they publish today; the weekly prices are the historical record, read with every recorded correction applied.

Prices are checked every Monday. Full method on the methodology page.

Revisions

None. This release is at revision 1, published October 4, 2026. A published number on this page is never edited in place. A correction becomes a new revision, listed here, with the old value kept.

Download and cite this release

Published under Creative Commons CC BY 4.0. Reuse any number with attribution. Nothing here asks for an account or an email address.

Any cut of this data by state, drug or program, within 24 hours: press@glpchart.com.

Every release

• October 2026 (this page), September 2026 data
• September 2026, August 2026 data
• The live price index, checked every Monday
• Every price change, week by week